Inhibrx Biosciences INBX
NASDAQ INBX
$90.25 -1.49 (-1.62%)
As of: Nov 10, 2026 · 3:08 PM EST

Inhibrx Biosciences (INBX) Receivables - Net (2023 - 2025)

Updated

Analysis

Inhibrx Biosciences (INBX) Receivables - Net (2023 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Inhibrx Biosciences 1.45 Bn 882.42 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 200,000.00
Sep 30, 2025 110,000.00
Jun 30, 2025 237,000.00
Mar 31, 2025 214,000.00
Dec 31, 2024 223,000.00
Sep 30, 2024 1.13 Mn
Jun 30, 2024 435,000.00
Dec 31, 2023 778,000.00
API Access

Inhibrx Biosciences Receivables - Net API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-net&ticker=INBX&period=max&api_key=YOUR_API_KEY